Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.0K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

64.7K
Overview
64.7K
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.3K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.

Frontiers in oncology·2026
Same author

Proton Beam Therapy for Large Localized Hepatocellular Carcinomas in Western Patients.

International journal of radiation oncology, biology, physics·2026
Same author

Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation.

bioRxiv : the preprint server for biology·2026
Same author

A Phase 1 Study of Neoadjuvant Cabozantinib in Combination With Radiation Therapy for Sarcomas of the Extremities.

American journal of clinical oncology·2026
Same author

Engineering scalable vascularized kidney organoids for in vivo glomerular filtration with human endothelial integration.

npj biomedical innovations·2026
Same author

CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Apr 30, 2026

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
07:45

Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

Published on: January 26, 2024

2.5K

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

Christian A Bauer, Edward Y Kim, Francesco Marangoni

    The Journal of Clinical Investigation
    |May 10, 2014
    PubMed
    Summary

    Regulatory T cells (Tregs) induce dysfunction in tumor-infiltrating cytotoxic T lymphocytes (CTLs) by altering local immune signaling. This Treg-mediated suppression requires antigen encounter within the tumor microenvironment.

    More Related Videos

    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
    10:13

    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

    Published on: May 6, 2019

    8.2K
    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
    07:36

    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

    Published on: June 12, 2021

    6.8K

    Related Experiment Videos

    Last Updated: Apr 30, 2026

    Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
    07:45

    Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis

    Published on: January 26, 2024

    2.5K
    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
    10:13

    Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

    Published on: May 6, 2019

    8.2K
    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
    07:36

    Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

    Published on: June 12, 2021

    6.8K

    Area of Science:

    • Immunology
    • Cancer Biology
    • T cell biology

    Background:

    • Regulatory T cells (Tregs) are crucial for immune homeostasis but their mechanisms in cancer remain unclear.
    • Understanding how Tregs modulate effector T cell function is vital for improving cancer immunotherapies.

    Purpose of the Study:

    • To investigate the mechanisms by which Tregs induce dysfunction in tumor-infiltrating cytotoxic T lymphocytes (CTLs).
    • To elucidate the spatial and temporal requirements for Treg-mediated suppression within the tumor microenvironment.

    Main Methods:

    • Developed a murine model of adoptive T cell therapy.
    • Utilized multiphoton intravital microscopy to observe Treg-APC interactions in vivo.
    • Analyzed T cell phenotypes, cytokine production, and co-stimulatory/co-inhibitory molecule expression.

    Main Results:

    • Tregs induced CTL dysfunction, characterized by suppressed effector functions and co-expression of PD-1 and TIM-3.
    • Treg-mediated CTL dysfunction required local T cell receptor (TCR) signals and antigen re-encounter within the tumor.
    • Tregs transiently interacted with antigen-presenting cells (APCs), reducing CD80/CD86 expression and promoting CTL exhaustion.

    Conclusions:

    • Tregs actively induce CTL dysfunction within the tumor microenvironment.
    • Tregs reprogram the tumor immune landscape by modulating APC co-stimulatory signals.
    • Targeting Treg-APC interactions may enhance anti-tumor T cell responses.